Document Type

Article

Publication Date

2016

Identifier

DOI: 10.21767/2472-5056.100011; PMCID: PMC4940046

Abstract

The clinical manifestations of typical hemolytic uremic syndrome (HUS) encompass a wide spectrum. Despite the potentially severe sequelae from this syndrome, treatment approaches remain supportive. We present the clinical course of a child who contracted Shiga toxin-positive E. coli (STEC) from a daycare center during an outbreak. Utilizing the modified Ham test which is a rapid, serum-based functional assay used to detect activation of the alternative pathway of complement as observed in atypical HUS, patient sera revealed evidence of increased complement activation in the acute phase of the syndrome but not after resolution. Further, this complement activation was attenuated by eculizumab in vitro, an effect that was replicated in vitro utilizing Shiga toxin as a stimulus of complement activation in normal serum. Our report suggests that complement blockade may be effective in the treatment of STEC-HUS when initiated early in the disease. Given the epidemic nature of the disease that limits the feasibility of randomized clinical trials, further studies are needed to determine the value of early eculizumab treatment in STEC-HUS.

Journal Title

J Clin Exp Nephrol

Volume

1

Issue

2

First Page

11

Last Page

11

MeSH Keywords

Hemolytic-Uremic Syndrome; Shiga Toxin; Escherichia coli Infections; eculizumab; Child Day Care Centers; Disease Outbreak; Child; Compliment Activation

Keywords

Hemolytic anemia; Hemolytic uremic syndrome; White blood cell

Download

Share

COinS